跳至主要内容
临床试验/NCT07040293
NCT07040293尚未招募不适用

Evaluation of the Efficacy and Safety of Absorbable Bone Wax and Traditional Bone Wax for Facet Fusion After Lumbar Fusion Surgery: A Multicenter, Randomized, Open-label, Superiority Clinical Trial

Shanghai Changzheng Hospital1 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2025年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
330
试验地点
1
主要终点
The clinical fusion rate of lumbar facet joints

研究概览

简要总结

Hemorrhage on the surface of cancellous bone presents a significant challenge in orthopedic surgery. Traditional bone wax, commonly utilized for hemostasis in bone wounds, is non-absorbable and associated with various complications, including pseudarthrosis, paralysis, venous sinus thrombosis, chronic inflammation, allergic reactions, and infections, thereby limiting its clinical utility. In contrast, absorbable bone wax, primarily composed of medical-grade water-soluble polymer materials, exhibits excellent biocompatibility. It is fully absorbed, excreted, or eliminated by the body without leaving toxic residues. This study employs a rigorous efficacy design to select an appropriate patient cohort for lumbar fusion surgery, based on specific inclusion and exclusion criteria. Participants are randomly assigned to either an experimental group receiving absorbable bone wax or a control group receiving traditional bone wax, facilitating a randomized, open-label, parallel-controlled clinical trial. This study aims to evaluate the comparative effects of absorbable bone wax versus traditional bone wax on the rate of bone fusion following hemostasis of bone wounds. The objective is to furnish robust evidence-based insights into the application of absorbable bone wax for bone wounds necessitating fusion, thereby establishing a safe, effective, and broadly applicable technique for bone wound hemostasis in clinical practice.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Participants must be aged between 18 and 75 years, with no restrictions on gender.
  • •Participants with conditions such as single-segment lumbar intervertebral disc protrusion, lumbar spondylolisthesis, and lumbar spinal stenosis who are scheduled to undergo posterior decompression, intervertebral fusion, and internal fixation surgery.
  • •Participants must be able to comprehend the objectives of the study, willingly participate, and provide informed consent by signing the consent form.

排除标准

  • •Individuals with a hemorrhagic predisposition or coagulation disorders, indicated by a prothrombin time (PT) of 18 seconds or greater, and those with a history of prolonged anticoagulant use.
  • •Individuals presenting with lumbar spine infections or fractures.
  • •Individuals with known allergies to materials such as polyethylene glycol, sodium carboxymethyl cellulose, and bone wax (including beeswax, paraffin, and isopropyl palmitate).
  • •Individuals whose conditions are critical, making it challenging to accurately assess the efficacy and safety of the equipment.
  • •Individuals deemed by researchers to have poor compliance, rendering them unable to fulfill the study requirements.
  • •Women who are currently pregnant, intend to become pregnant within the past year, or are breastfeeding.
  • •Individuals who have participated in other clinical trials within the preceding 30 days to prevent cross-interference.
  • •Individuals with significant complications or comorbidities, such as severe cardiovascular, hepatic, renal, or other chronic conditions that could influence surgical risks and research outcomes.
  • •Individuals identified by researchers as having a life expectancy of less than six months.
  • •Individuals with severe osteoporosis, defined as a bone mineral density T-score of ≤-2.5 accompanied by fragility fractures.
  • •Any other individuals deemed unsuitable for participation in this clinical trial by the researchers.

研究组 & 干预措施

Absorbable bone wax gruop

Experimental

干预措施: Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint (Device)

Traditional bone wax group

Active Comparator

干预措施: Traditional bone wax for hemostasis in the osteotomy surface of the facet joint (Device)

结局指标

主要结局

The clinical fusion rate of lumbar facet joints

时间窗: 6 months

The proportion of individuals achieving the clinical fusion standard of the facet joint was assessed within each group. Six months postoperatively, the fusion status of the facet joints at the surgical segments was evaluated using continuous thin-slice CT plain scans combined with three-dimensional reconstruction images of the lumbar vertebrae. The evaluation criteria were based on the guidelines established by Ren et al. (2020) in their study on modified facet joint fusion for lumbar degenerative disease. According to these criteria, clinical fusion is confirmed when one side of the facet joint attains grade I or grade II radiological fusion standards.

次要结局

  • The success rate of hemostasis within three minutes(3 minutes)
  • Postoperative wound healing(14 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Haifeng Wei, MD, PhD

vice director

Shanghai Changzheng Hospital

研究点 (1)

Loading locations...

相似试验